Početna › Dermatomiozitis › Massachusetts
Kliničke studije za Dermatomiozitis u državi Massachusetts
5 studija za Dermatomiozitis traži sudionike na lokacijama u državi Massachusetts.
Gradovi u državi Massachusetts
Službeni tekst studije (engleski)
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Research Site, Boston
U tijeku regrutacijaFaza 3
Od 18 do 75 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06455449Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT03816345RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
U tijeku regrutacijaFaza 2/3
Od 6 do 75 godina · Oba spola · Ažurirano 17. ruj 2026. · NCT06154252A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- Brigham and Women's Hospital, Boston
- CTC - Brigham & Women's Hospital, Boston
- CTH - Brigham & Women's Hospital, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT05895786A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Brigham And Womens Hospital, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 14. srp 2026. · NCT07115745Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.